(Q47789263)

5 February 2018

title

Pharmacokinetic analysis of the FDA guidance for industry--'Topical dermatologic corticosteroids: in vivo bioequivalence'. (English)

1 reference

5 February 2018

1 reference

Claudia S Leopold

1

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 July 2003

1 reference

5 February 2018

European Journal of Pharmaceutics and Biopharmaceutics

published in

1 reference

5 February 2018

volume

56

1 reference

5 February 2018

issue

1

1 reference

5 February 2018

page(s)

53-58

1 reference

5 February 2018

Bioequivalence of topical dermatological dosage forms--methods of evaluation of bioequivalence

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

Bioassays Used in Development of Topical Dosage Forms

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

Relationship between In Vivo Skin Blanching and In Vitro Release Rate for Betamethasone Valerate Creams

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

New approaches to assess topical corticosteroid bioequivalence: pharmacokinetic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

Use of reflectance spectrophotometry in the human corticosteroid skin blanching assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

The cutaneous corticosteroid vasoconstriction assay: a reflectance spectroscopic and laser-Doppler flowmetric study

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling.

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

How accurate is the determination of the relative bioavailability of transdermal drug formulations from pharmacodynamic response data?

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

The maximum pharmacodynamic effect as a response parameter: pharmacokinetic considerations.

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

Percutaneous penetration of local anesthetic bases: pharmacodynamic measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

The effect of cream and ointment bases on the steady state penetration of permeants through intact skin: the reciprocal of the onset time of a pharmacodynamic effect as parameter of response

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

Carrier-mediated transport of monocarboxylic acids in primary cultured epithelial cells from rabbit oral mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

Enhancing effects of lipophilic vehicles on skin penetration of methyl nicotinate in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0939-6411%2803%2900045-6

7 January 2021

10.1016/S0939-6411(03)00045-6

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018